Navigation Links
New Data Shows Once a Day Lamictal XR is Effective in Treating,Patients with Partial Seizures

Data Presented at the American Academy of Neurology Annual Meeting Show Approximately 50 Percent Reduction in Partial Seizures

BOSTON, May 01, 2007 /PRNewswire/ -- Data from two clinical trials presented today at the American Academy of Neurology (AAN) meeting suggest that an investigational once daily extended release formulation of Lamictal(R) (lamotrigine) is effective as add-on treatment in patients with partial epilepsy with and without secondary generalization. Lamictal XR Extended- Release Tablets are currently in development for the treatment of epilepsy. If approved, it will be the first extended release, new generation epilepsy treatment taken once-daily.

Data from the ARMOR study, an international, multi-center, randomized, double-blind, placebo-controlled trial, showed that the new once-daily, extended release formulation reduced partial seizures by 46 percent, while patients taking placebo experienced a reduction of 24 percent over the entire 19-week treatment period. The study also showed significant overall reduction in seizure frequency in both the escalation and maintenance treatment phases. In addition, the study showed that 42 percent of patients treated with Lamictal XR reduced their frequency of seizures by at least half by the end of the 19-week treatment period.

The second study, COMPASS, showed that patients could be switched from Lamictal(R) immediate release (IR) to Lamictal XR while maintaining comparable blood levels of lamotrigine.

"These data are important because they show that the extended release formulation of Lamictal reduces the frequency of seizures. The once daily dosing regimen may also provide a more convenient treatment option for patients," said Dean Naritoku, M.D., Professor of Neurology and Pharmacology, Southern Illinois University, Springfield, IL. "In addition, when compared to Lamictal immediate release, given twice a day, the new investigatio
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:8/3/2015)... 3, 2015  Array BioPharma Inc. (NASDAQ: ... quarter and full year of its fiscal year ... Chief Executive Officer of Array, noted, "Binimetinib and encorafenib, ... on track for regulatory submissions in 2016. Additional ... and BRAF-mutant colorectal cancer further validate the value ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR ... specializing in the development, manufacturing, and marketing of branded ... annual general meeting of shareholders (the "Meeting") will be ... Beijing time. The meeting will be held at No.699-18, ...
... /PRNewswire-iReach/ -- Global Information Inc. is pleased to ... Therapy market: Global Protein Therapeutics Market ... become one of the most effective clinical methods to ... metabolic disorders. While worldwide healthcare spending has decline in the ...
Cached Medicine Technology:Simcere Pharmaceutical Group Provides Notice of Annual General Meeting 2New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015 2
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest ... pharmacogenetic lab testing and precision medicine solutions that can help pharmacists and other ... more than 8.6 million adverse drug events are reported in the U.S. ...
(Date:8/3/2015)... ... 2015 , ... Dental practice in Los Angeles , Sunset Plaza Dental, ... that general health emergencies, such as broken arms or a heart attack, should be ... turn to during a dental emergency. This is important, because dental trauma is extremely ...
(Date:8/3/2015)... ... August 03, 2015 , ... Results of a comprehensive ... Healthcare Research and Policy Analysis show widespread support for the U.S. Affordable Care ... or strongly agreed that the controversial law passed in 2010 had “more good ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... The U.S. ... under the chin. Kybella is similar to deoxycholic acid, which occurs naturally in the ... the main options to treat this area of the body. These are invasive procedures ...
(Date:8/3/2015)... ... 03, 2015 , ... Illinois Health & Science (IHS) has completed the purchase ... includes all of IBAM NA’s cyclotron sites and research and development facilities. ... business, as well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2
... Palomar Medical Technologies, Inc. (Nasdaq: PMTI ), ... treatments, will hold its quarterly conference call of its 2009 ... 11:30 AM Eastern Time. If you would like to participate, ... that day. The telephone replay will be available one hour ...
... , TAMPA, Fla., July 23 Bay Area ... chemical drugs and armed himself with a movie to help ... preventable illness, Burton found an alarming connection between America,s food ... Now he,s going to tell the world what he found. ...
... what a tale my thoughts could tell" Gordon Lightfoot ... and some new businesses, are banking on a brain imaging ... hidden thoughts, such as lies, truths or deep desires. ... Rutgers University provides evidence that fMRI can be used in ...
... risen over recent years. This is fact, but what is ... health centres have shown that family conflict is not a ... Primaria are striking: in Spain, 24% of women take antidepressants ... of psychopharmaceuticals is often related to family or work-related problems. ...
... , PRINCETON, N.J., July 23 The National ... several member associations today urged President Obama and members of Congress to ... most pervasive and costly diseases, a priority in reforming the U.S. healthcare ... to the President and lawmakers, NCDP said a national response to diabetes ...
... , BATESVILLE, Ind., July 23 Hill-Rom Holdings, Inc.,s, ... be issued Thursday, August 6, 2009. You are invited to participate ... a.m. EDT. , Earnings Release: Hill-Rom Holdings, ... 2009 will be released to the public after the NYSE close on ...
Cached Medicine News:Health News:Palomar Medical Technologies To Host Second Quarter 2009 Financial Results Conference Call and Webcast on July 30, 2009 2Health News:Nurse Turned Filmmaker Makes Lifesaving Film 2Health News:Can brain scans read your mind? 2Health News:Can brain scans read your mind? 3Health News:Almost 1 quarter of Spanish women take antidepressants 2Health News:NCDP Health Care Reform Recommendations Advocate for Diabetes Prevention, Treatment and Care 2Health News:NCDP Health Care Reform Recommendations Advocate for Diabetes Prevention, Treatment and Care 3Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Third Quarter Earnings Webcast 2
This portable resource provides definitions for medical acronyms and abbreviations....
Stedman's Medical Dictionary includes charts and tables and navigation and search tools....
With Skyscape's smARTlink technology, Tabers can cross-index with other clinical and drug prescription products from Skyscape to provide an integrated source of clinical information....
CPTMeister is a coding reference based on the Physicians' Current Procedural Terminology (CPT) codes developed by the American Medical Association. It is an iSilo document composed of more than 2,000...
Medicine Products: